CJC-1295 With DAC vs Tesamorelin: Research Comparison
A Side-By-Side Research Comparison Of CJC-1295 With DAC And Tesamorelin - two GHRH analogs with contrasting half-life profiles. This Reference Compares Mechanism, Evidence Tier, Molecular Identity, And Pharmacokinetics For Qualified Researchers. For In Vitro Laboratory Research Use Only. Not Medical Advice Or Dosing Guidance.
Side-By-Side Comparison
| CJC-1295 With DAC | Tesamorelin | |
|---|---|---|
| Category | Muscle Growth & Performance | Muscle Growth & Performance |
| Compound Class | Long-acting synthetic GHRH analog with Drug Affinity Complex (DAC) albumin-binding moiety | Synthetic GHRH analog with trans-3-hexenoic acid modification at N-terminus; FDA-approved for HIV lipodystrophy |
| Evidence Tier | Research Compound | Approved Drug |
| Molecular Target | GHRH receptor (GHRHR) on pituitary somatotrophs; sustained GH and IGF-1 elevation | GHRH receptor (GHRHR) on pituitary somatotrophs; GH/IGF-1 axis stimulation; preferential visceral fat metabolism |
| Molecular Weight | 3647.1 Da | 5135.9 Da |
| Amino Acid Sequence | tetrasubstituted GRF(1-29) + DAC | hGHRH(1-44) with trans-3-hexenoyl |
| CAS Number | 446262-90-4 | 218949-48-5 |
| Half-Life | ~6-8 days (albumin-bound, DAC) | ~26-38 minutes |
| Studied For | GH pulsatile release research, GH-axis anti-aging, Growth hormone deficiency, Extended GH secretion | HIV-associated lipodystrophy (FDA approved), Hepatic fat / NAFLD research, Cognition research in aging/HIV, GH deficiency |
About CJC-1295 With DAC
A long-acting growth-hormone-releasing peptide; banned in sport.
Read The Full CJC-1295 With DAC MonographAbout Tesamorelin
An FDA-approved growth-hormone-releasing hormone analog used to reduce visceral fat in HIV-associated lipodystrophy; banned in sport.
Read The Full Tesamorelin MonographKey Differences
- Evidence tier differs: CJC-1295 With DAC is classified as Research Compound; Tesamorelin is classified as Approved Drug.
- Reported half-life differs: CJC-1295 With DAC at ~6-8 days (albumin-bound, DAC) versus Tesamorelin at ~26-38 minutes.
- Primary molecular target differs: CJC-1295 With DAC acts on GHRH receptor (GHRHR) on pituitary somatotrophs; sustained GH and IGF-1 elevation; Tesamorelin acts on GHRH receptor (GHRHR) on pituitary somatotrophs; GH/IGF-1 axis stimulation; preferential visceral fat metabolism.
Continue Researching
CJC-1295 With DAC · Tesamorelin · Compare Tool · Research Library
This Comparison Is Provided For In Vitro Laboratory Research Use Only. Not For Human Consumption, Diagnosis, Or Treatment. See The Full Research Disclaimer.